We provide the first evidence in a mouse model that tumours present citrullinated epitopes that can stimulate both Th1 and regulatory CD4 responses and suggest that characterisation of responses elicited by epitopes identified by peptide elution is necessary to optimise candidate selection for tumour therapy. Here, CD4 is linked to neoplasm.